Report error Found 34 of ic50 data for polymerid = 50004830
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 2.5nMAssay Description:In vitro experiments show that the intrinsic antiplasmodial activity of ethylcarbonate ester ELQ-337 is indistinguishable from ELQ-300, with IC50 val...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 2.5nMAssay Description:In vitro experiments show that the intrinsic antiplasmodial activity of ethylcarbonate ester ELQ-337 is indistinguishable from ELQ-300, with IC50 val...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 2.5nMAssay Description:In vitro experiments show that the intrinsic antiplasmodial activity of ethylcarbonate ester ELQ-337 is indistinguishable from ELQ-300, with IC50 val...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 2.5nMAssay Description:In vitro experiments show that the intrinsic antiplasmodial activity of ethylcarbonate ester ELQ-337 is indistinguishable from ELQ-300, with IC50 val...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 2.70nMAssay Description:In vitro experiments show that the intrinsic antiplasmodial activity of ethylcarbonate ester ELQ-337 is indistinguishable from ELQ-300, with IC50 val...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 3nMAssay Description:In vitro experiments show that the intrinsic antiplasmodial activity of ethylcarbonate ester ELQ-337 is indistinguishable from ELQ-300, with IC50 val...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 3.10nMAssay Description:In vitro experiments show that the intrinsic antiplasmodial activity of ethylcarbonate ester ELQ-337 is indistinguishable from ELQ-300, with IC50 val...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 3.10nMAssay Description:In vitro experiments show that the intrinsic antiplasmodial activity of ethylcarbonate ester ELQ-337 is indistinguishable from ELQ-300, with IC50 val...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 3.5nMAssay Description:In vitro experiments show that the intrinsic antiplasmodial activity of ethylcarbonate ester ELQ-337 is indistinguishable from ELQ-300, with IC50 val...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 3.90nMAssay Description:In vitro experiments show that the intrinsic antiplasmodial activity of ethylcarbonate ester ELQ-337 is indistinguishable from ELQ-300, with IC50 val...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 6nMAssay Description:In vitro experiments show that the intrinsic antiplasmodial activity of ethylcarbonate ester ELQ-337 is indistinguishable from ELQ-300, with IC50 val...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 8.20nMAssay Description:In vitro experiments show that the intrinsic antiplasmodial activity of ethylcarbonate ester ELQ-337 is indistinguishable from ELQ-300, with IC50 val...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 1.03E+4nMAssay Description:Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocyte assessed as inhibition of [3H]chloroquine uptake...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 1.05E+4nMAssay Description:Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocyte assessed as inhibition of [3H]chloroquine uptake...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 1.25E+4nMAssay Description:Inhibition of Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocyte assessed as inhibition of [3H]-CQ transport incubated for 1.5 hrs by m...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 1.30E+4nMAssay Description:Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocytes assessed as reduction in [3H]-chloroquine uptak...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 1.30E+4nMAssay Description:Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocyte assessed as inhibition of [3H]chloroquine uptake...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 1.56E+4nMAssay Description:Inhibition of Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocyte assessed as inhibition of [3H]-CQ transport incubated for 1.5 hrs by m...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocyte assessed as inhibition of [3H]chloroquine uptake...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocytes assessed as reduction in [3H]-chloroquine uptak...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 3.30E+4nMAssay Description:Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocytes plasma membrane assessed as reduction of [3H]-c...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 3.60E+4nMAssay Description:Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 chloroquine resistance transporter expressed in xenopus laevis oocytes assessed as inhi...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 5.40E+4nMAssay Description:Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocytes plasma membrane assessed as reduction of [3H]-c...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 5.50E+4nMAssay Description:Inhibition of Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocyte assessed as inhibition of [3H]-CQ transport incubated for 1.5 hrs by m...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 5.80E+4nMAssay Description:Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 chloroquine resistance transporter expressed in xenopus laevis oocytes assessed as inhi...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 6.30E+4nMAssay Description:Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocytes plasma membrane assessed as reduction of [3H]-c...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 6.40E+4nMAssay Description:Inhibition of Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocyte assessed as inhibition of [3H]-CQ transport incubated for 1.5 hrs by m...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 6.60E+4nMAssay Description:Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocytes plasma membrane assessed as reduction of [3H]-c...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 6.80E+4nMAssay Description:Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocytes plasma membrane assessed as reduction of [3H]-c...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 6.90E+4nMAssay Description:Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 chloroquine resistance transporter expressed in xenopus laevis oocytes assessed as inhi...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 8.50E+4nMAssay Description:Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocytes plasma membrane assessed as reduction of [3H]-c...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 1.80E+5nMAssay Description:Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocytes plasma membrane assessed as reduction of [3H]-c...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 2.28E+5nMAssay Description:Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocytes assessed as reduction in [3H]-chloroquine uptak...More data for this Ligand-Target Pair
TargetChloroquine resistance transporter(malaria parasite P. falciparum)
Oregon Health & Science University
US Patent
Oregon Health & Science University
US Patent
Affinity DataIC50: 3.21E+5nMAssay Description:Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocytes plasma membrane assessed as reduction of [3H]-c...More data for this Ligand-Target Pair
